<DOC>
	<DOCNO>NCT00001623</DOCNO>
	<brief_summary>Bone marrow transplant ( BMT ) one accepted therapy use treat leukemia . However , BMT risk complication . One potentially life-threatening complication know graft-versus-host disease ( GVHD ) . The GVHD reaction cause incompatibility donor cell recipient cell . Antigens find recipient cell recognize donor transplant white blood cell lymphocytes . These lymphocytes begin attack recipient cell tissue may lead death . One effective way prevent reaction remove lymphocyte transplant marrow . Unfortunately , without lymphocyte recipient immune system lower may result relapse leukemia infection . Researchers show perform effective BMT removing lymphocytes prior transplant later add lymphocyte back . This technique reduce potential GVHD preserve graft-versus-leukemia ( GVL ) effect transplant . In study researcher plan use peripheral blood lymphocyte remove rather bone marrow . In order increase number progenitor cell , cell responsible correct leukemia , donor receive dos G-CSF prior transplant . G-CSF ( granulocyte colony stimulate factor ) growth factor increase production progenitor cell donor blood stream . The study break two part . The first part study attempt determine peripheral blood lymphocyte remove prevent GVHD preserve GVL effect transplant . In second part study , patient receive transplant lymphocyte added-back two separate occasion order reduce chance relapse infection . The study design treat 55 patient age 10 60 year follow progress 5 year .</brief_summary>
	<brief_title>Bone Marrow Transplant Studies Safe Effective Treatment Leukemia</brief_title>
	<detailed_description>One effective way prevent lethal graft-versus-host disease ( GVHD ) allogeneic bone marrow transplantation ( BMT ) leukemia remove T-lymphocytes transplanted marrow . The reduced early mortality T cell depletion however offset increase risk leukemic relapse infection . We show bone marrow transplant leukemia deplete T cell elutriation follow delayed add-back donor T cell reduce GVHD preserve immune response hematologic malignancy ( so-called graft-versus-leukemia ( GVL ) graft-versus-myeloma effect ) . The study highlight possible benefit large dos marrow progenitor cell transplant outcome . GVHD reduce prevent T cell depletion marrow . The first objective BMT study prevent GVHD transplant conserve GVL reactivity . This prerequisite second objective determine risk GVHD benefit GVL add-back donor lymphocytes . These study provide basis plan trial add back donor lymphocyte select vitro confer immunity infectious agent residual leukemia without cause GVHD . In study evaluate use T cell deplete peripheral blood progenitor cell ( PBPC ) ( instead bone marrow ) optimize stem cell lymphocyte dose . Donors give G-CSF mobilized PBPC harvest leukapheresis . To minimize acute GVHD , transplant T cell deplete , use new technique develop normal volunteer improve T cell depletion reduce stem cell loss ( protocol 96-H-0049 ) . The study two phase : The first phase evaluate engraftment GVHD follow T cell deplete PBPC transplant . Stopping rule use make modification protocol event graft failure . Cyclosporine withdrawn protocol incidence acute GVHD low absent . In second phase patient receive add-back donor lymphocyte day 45 day 100 post transplant prevent relapse confer donor-immune function . The risk acute GVHD follow procedure determine . It plan treat 55 patient age 10 60 year . The end point study graft take ; acute chronic GVHD , leukemic relapse , transplant-related cause mortality , cytomegalovirus reactivation leukemia-free survival . Patients follow 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>INCLUSION CRITERIAPATIENT : Ages 10 55 year . Chronic myelogenous leukemia , category : chronic phase , accelerate phase blast transformation . Acute lymphoblastic leukemia , category : Adults ( great 18 year ) first remission high risk feature ( present leukocyte count great 100,000 per cu mm , Karyotypes t9 ; 22 , t4 , t19 , t11 , biphenotypic leukemia ) . All second remission , primary induction failure , partially respond untreated relapse . Acute myelogenous leukemia ( AML ) : AML first remission Except AML good risk karyotype : AML M3 ( t15 ; 17 ) , AML M4Eo ( inv 16 ) , AML ( 8 ; 21 ) . All AML second subsequent remission , primary induction failure resistant relapse . Myelodysplastic syndrome , category : refractory anemia excess blast , transformation acute leukemia , chronic myelomonocytic leukemia . Multiple myeloma follow initial disease control chemotherapy . Chronic lymphocytic leukemia ( CLL ) prolymphocytic leukemia , remission partial remission follow fludarabine treatment . Richter transformation CLL . No major organ dysfunction preclude transplantation . DLCO great 65 percent predict . Left ventricular ejection fraction : great 40 percent predict . ECOG performance status 0 1 . Informed consent give . Informed consent parent minor . Women childbearing age negative pregnancy test may participate . EXCLUSION CRITERIA : Pregnant . Age great 55 less 10 . ECOG performance status 2 . Severe psychiatric illness . Mental deficiency sufficiently severe make compliance BMT treatment unlikely , make informed consent impossible . Major anticipated illness organ failure incompatible survival BMT . DLCO le 65 % predict . Left ventricular ejection fraction : le 40 % predict . Serum creatinine great 3 mg/dl . Serum bilirubin great 4 mg/dl . Transaminases great 3 x upper limit normal . HIV positive . History malignancy except basal cell squamous carcinoma skin , positive PAP smear subsequent negative follow ( patient ) . INCLUSION CRITERIADONOR : HLA 6/6 5/6 match sibling donor . Fit receive GCSF give peripheral blood stem cell ( normal blood count , normotensive , history stroke ) . Informed consent give . EXCLUSION CRITERIA DONOR : Pregnant . Severe psychiatric illness . Mental deficiency sufficiently severe make compliance BMT treatment unlikely , make informed consent impossible . Donor unfit receive GCSF undergo apheresis . ( Uncontrolled hypertension , history stroke , thrombocytopenia ) . HIV positive .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 18, 2016</verification_date>
	<keyword>Peripheral Blood Stem Cells</keyword>
	<keyword>Graft-Versus-Leukemia</keyword>
	<keyword>Graft v . Host Disease</keyword>
	<keyword>Whole Body Irradiation</keyword>
	<keyword>Donor Apheresis</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Graft-Versus-Myeloma</keyword>
	<keyword>Leukemic Relapse</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Acute Myelogenous Leukemia ( AML )</keyword>
	<keyword>Chronic Myelogenous Leukemia ( CML )</keyword>
	<keyword>Acute Lymphoblastic Leukemia ( ALL )</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Chronic Lymphocytic Leukemia ( CLL )</keyword>
</DOC>